Fig 1: Protein expression of IL-18, NF-κB and vWF in each group. IL-18, interleukin-18; NF-κB, nuclear factor-κB; vWF, von Willebrand factor.
Fig 2: AABR07032261.5 silencing promotes pyroptosis in the cellular PD model. (A) Relative expression of AABR07032261.5 in the cellular PD model transfected with siRNAs targeting AABR07032261.5. lncRNA levels were analyzed by quantitative RT-PCR. (B) Effects of AABR07032261.5 silencing on proliferation in the cellular PD model. Cell proliferation was assessed by MTS assay. (C) Influence of AABR07032261.5 silencing on apoptosis in the cellular PD model. Flow cytometry was performed to detect apoptotic cells. (D and E) Altered IL-1β and IL-18 secretion in the cellular PD model with silenced AABR07032261.5 expression. IL-1β and IL-18 contents in cell cultures were measured by ELISA. (F) Differential expression of pyroptosis marker proteins in the cellular PD model caused by AABR07032261.5 knockdown. (G) On the basis of the gray values, quantitative analysis of proteins was conducted for Western blot results. (H) Differential expression of AABR07032261.5-interacting microRNAs in the cellular PD model with AABR07032261.5 knockdown. (I) Relative Stat3 mRNA levels in the cellular PD model with silenced AABR07032261.5 expression. Quantitative RT-PCR was used to detect microRNA and mRNA levels. *P < 0.05; **P < 0.01.
Fig 3: KORs inhibit post-CPB NLRP3 inflammasome expression in rats' brain tissue. (a) NLRP3 inflammasome expression level was detected using western blotting. (b) Release of ROS in a different group of rats was visualized with IF (scale bar = 50 µm). (c) Expression levels of preform inflammatory proteins, pro-Caspase-1, pro-IL-1ß, and pro-IL-18, were detected with western blotting. (d) Contents of mature IL-1ß (pg/ml) and IL-18 (ng/ml) in rats' brain tissue samples were determined using ELISA. All data in charts were represented as mean ± standard deviation; “*” was labeled when the comparative significance between groups (p value) was less than 0.05.
Fig 4: Western blot analysis of IκBα and p65. A, control; B, IL-18 treatment; C, IL-18+QNZ treatment. NF-κB, nuclear factor-κB; IκBα, inhibitor of NF-κB.
Fig 5: Immunofluorescence results. FITC-labeled secondary antibody appeared as green fluorescence following binding to p-p65. The nucleus appeared as blue fluorescence following DAPI staining (magnification, x200). A, control; B, IL-18 treatment; C, IL-18+QNZ treatment.
Supplier Page from CUSABIO Technology LLC for Rat Interleukin 18,IL-18 ELISA Kit